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Introduction 
 
Currently in the UK, oesophageal cancer has a high mortality rate with an estimated 5-year 
survival rate of 15% [1]. Many patients with locally advanced oesophageal cancer are 
treated with chemo-radiation. A large percentage of these patients will experience local 
recurrence within the first two years post-treatment [2,3]. Some studies suggest that 
persistent disease may be a result of inaccurate GTV delineation [4]. Consequently, accurate 
detection and delineation of the extent of disease is important. Improving this definition of 
the gross tumour volume (GTV) remains a challenge in oesophageal cancer [5,6].  
 
The role of fluoride-18 fluorodeoxyglucose (FDG) positron emission tomography - computed 
tomography (PET-CT) imaging has been explored in recent years, with applications including 
tumour staging, target delineation and assessment of tumour response to treatment [7,8]. 
PET-CT can assist in identifying the metabolically active tumour but there remains 
uncertainty in how this information should be used [9-12]. Some studies suggest PET-CT 
may enable more accurate tumour delineation, compared to CT alone [6, 9, 13]. There are 
many difficulties in integrating PET-CT to the treatment planning process; primarily because 
the staging PET-CT is typically acquired prior to a decision to proceed with non-surgical 
treatment. Consequently these scans are not acquired in a radiotherapy treatment position. 
An additional PET-CT scan in the treatment position could be acquired but is resource 
intensive, onerous for patients and results in an increased radiation dose. Alternatively, the 
diagnostic PET-CT could be incorporated into the planning pathway using image co-
registration, but the accuracy of this co-registration process is essential. Rigid co-registration 
in a region of interest may be suboptimal due to positional differences between the PET-CT 
and planning CT (pCT). Deformable image registration (DIR) provides an alternative option. 
It has many applications in radiotherapy treatment planning including calculating 
accumulative dose over a radiotherapy treatment course, and auto-segmentation for 
target/organ at risk delineation/to account for contour changes in adaptive radiotherapy 
[14-21]. 
 
Analysis of the pattern of local recurrence is critical in evaluating the quality of the 
radiotherapy treatment. DIR has been used for this purpose in head and neck cancer [22-
24]. It represents a promising method to evaluate local recurrence and to determine 
whether these recurrences are within the original treatment planning volume. DIR can be 
used to examine the pattern of recurrence relative to the metabolically active PET-CT 
volume, to determine whether this represents a potential target for dose escalation 
strategies.  
 
This study aims to quantify the accuracy of co-registration of diagnostic PET-CT and relapse 
imaging to the pCT, using both DIR and rigid registration, and to correlate the site of local 
recurrence with pre-treatment PET avidity.  
 
METHODS AND MATERIALS 
 
Patients 
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Data was collected retrospectively for 10 patients with oesophageal cancer who were 
treated between February 2009 and August 2010 with a combination of chemotherapy and 
external beam radiotherapy. 6 of these patients later experienced local recurrence.  
 
Imaging 
 
As part of routine clinical staging, all patients underwent an FDG PET-CT scan (Discovery ST, 
GE Medical Systems, Milwaukee, Wisconsin) an average of six weeks prior to treatment 
commencing (range 4-137 days). Patients were scanned on a curved couch-top with arms 
raised. Images were acquired from skull base to upper thigh, 60 minutes after a 400MBq 
dose of intravenous fluorine-18 FDG. The CT component of the PET-CT was performed 
according to a standardized protocol with the following settings: 140 kV; 80 mAs; tube 
rotation time 0.5 s per rotation; pitch 6; section thickness 3.75 mm (to match the PET 
section thickness). Patients maintained normal shallow respiration during the CT acquisition. 
No iodinated contrast material was administered. No immobilisation equipment was used.  
 
A CT scan for treatment planning was acquired with a 24 or 40 slice, wide-bore scanner 
equipped with a flat couch-top (Somatom Sensation, Siemens Medical Systems, Erlangen, 
Germany). Patients were scanned in the supine position immobilised on a wing-board with 
their arms above their heads. One patient was scanned with their arms down and 
immobilised in a 5-point thermoplastic mask. Intravenous contrast was administered and 
5mm slices were acquired from lung apices to iliac crests.  
 
Recurrence imaging was acquired according to standard diagnostic CT protocols. Patients 
were scanned on a standard curved couch-top and no immobilisation equipment was used.  
 
Radiotherapy Treatment Planning 
 
All patients were treated according to the NCRI UK SCOPE1 trial protocol [25] and received a 
conformal radiotherapy treatment of 50Gy in 25 treatment fractions to the planning target 
volume (PTVTP). The PTVTP was derived from a GTVTP contoured on the pCT using visual 
cross-reference with the unregistered FDG PET-CT scan and the endoscopic ultrasound 
(EUS). The GTVTP was extended 2cm superiorly and inferiorly along the length of the 
oesophagus, and 1cm in all other directions to form a CTVTP. Finally the PTVTP was derived 
from the CTVTP plus a margin of 1cm superiorly and inferiorly, and 0.5cm in all other 
directions. 
 
Treatment planning was carried out using the Xio (version 4.4) treatment planning system 
(Elekta CMS, Stockholm, Sweden) and a 3D conformal treatment technique with 6MV beams 
including an anterior and posterior field and two lateral fields angled away from the spinal 
cord. Each plan aimed to cover 95% of the PTVTP with 99% of the prescribed dose [25]. 
 
Deformable and Rigid Image Co-registration 
 
All DIR and rigid registrations were performed using Mirada (version 1.4, RTx, Mirada 
Medical, Oxford, UK). The DIR algorithm was evaluated in previous work [26]. For all 10 
patients, the DIR was performed over the whole image and qualitatively evaluated by a 
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physicist and radiation oncologist. Rigid registrations were carried out by performing an 
initial manual co-registration followed by a local, automatic rigid registration within a region 
of interest defined by the GTVTP plus a 5cm margin in the superior/inferior and lateral 
directions and 8cm in the anterior/posterior direction.  This region of interest was defined 
to allow the inclusion of sufficient anatomical landmarks to facilitate co-registration but to 
minimise the influence of positional differences distant from the GTVTP. 
 
Validation of Registration 
 
For each patient, the accuracy of the DIR, compared to rigid registration, was qualitatively 
reviewed by a radiation oncologist and physicist team blinded to method of co-registration. 
A visual assessment was carried out looking at the coincidence of anatomical landmarks 
including oesophagus, trachea and aorta. The local deformation was evaluated by visually 
examining the deformation grid. Co-registrations were classified as clinically acceptable or 
unacceptable, and preference for which registration was considered superior was 
documented. 
 
A quantitative assessment was performed to evaluate the accuracy of co-registration. It 
involved comparing outlines of the trachea (from sternal notch to carina), oesophagus (from 
level of sternal notch to gastro-oesophageal junction) and descending aorta (from level of 
sternal notch to level of gastro-oesophageal junction) on the PET-CT, pCT and relapse CT. 
Structures were then transferred from the PET-CT and relapse CT to the pCT, via rigid 
registration and DIR. Four positional metrics were calculated using ImSimQA software 
(v3.1.5, OSL, Shrewsbury, UK); conformity index (CI); dice similarity coefficient (DSC); 
sensitivity index (SI); and inclusion index (Incl).  The DSC is described as the size of the union 
of two datasets divided by the average size of the datasets. Values range from 0 to 1 with 0 
describing structure with no overlap and 1 describing structures that overlap completely. 
The CI is defined as the ratio of the overlapping region of two structures to the total area 
covered by both structures. The IncI describes the probability that a voxel of one structure is 
really a voxel of a reference structure. The SI describes the probability that one structure 
matches a reference structure and can be referred to as the overlapping index.    
 ܦ�ܥ =  2ሺ��௘௙ ת �௘���ሻ��௘௙ + �௘���   ܥ� = ��௘௙ ת �௘�����௘௙ ׫ �௘���   ��� =  ��௘௙ ת �௘����௘���    �� =  ��௘௙ ת �௘�����௘௙  
 
Note that Vref is the volume/area of a reference structure (in this case, the structure 
contours on the pCT) and Veval is the volume/area of the structure to be evaluated (i.e. the 
structure contoured on the PET-CT and relapse CT). 
 
DIR in deriving a PET-CT based GTV 
 
Following the co-registration feasibility investigation, DIR was used to derive a GTV using a 
combination of PET-CT and pCT. For all 10 patients, the metabolically active volumes were 
contoured by a physicist on the PET-CT images, using 50% of maximum SUV thresholding. 
Volumes were reviewed by a dual-certified nuclear medicine physician and radiologist, and 
contours edited manually if required. Structures were transferred to the pCT using DIR. 
Contours were reviewed by a radiation oncologist and the entire circumference of the 
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involved oesophagus, as determined by the PET-CT, was outlined to define the GTV (GTVPET-
CT). This volume was grown according to the clinical protocol to produce a PET-CT derived 
PTV (PTVPET-CT). For 6 patients who experienced local recurrence, the relapse volume 
(GTVrelapse) was contoured on the diagnostic relapse CT. DIR was used to transfer this volume 
to the pCT where, if required, it was edited by a radiation oncologist.  
 
Comparison of Volumes 
 
For each patient, both the volume and lengths of the GTVPET-CT and PTVPET-CT structures were 
compared to the original treatment planning structures (GTVTP and PTVTP). A visual 
comparison of the location of the relapse volumes (GTVrelapse), relative to both the PTVPET-CT 
and PTVTP, determined whether the site of relapse was contained within these structures. 
The IncI was used to examine whether any correlation exists between GTVrelapse and the PET-
avid volume. Dosimetric analysis was carried out by measuring the V95%, i.e. the volume 
receiving 95% of the prescribed treatment dose, of each structure to assess coverage.  
 
RESULTS 
 
Qualitative Assessment of Registration 
 
All co-registrations of PET-CT to pCT were considered clinically acceptable; DIR was rated as 
superior to rigid registration for all 10 patients and the preferred method for registration.  A 
representative example is shown in Figure 1.  The co-registration of the relapse CT to pCT 
was considered acceptable for five of six patients. For one patient, co-registration was not 
possible as the patient had had a stent inserted into the oesophagus at the time of the 
relapse CT. This resulted in large variations to the position of the trachea and aorta 
compared to the pCT.  
 
Figure 1  
A visual examination of the oesophagus and aorta structures mapped from the PET-CT to 
the planning CT via (a) rigid registration and (b) DIR. 
 
 
Quantitative Assessment of Registration 
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The positional metrics analysis of co-registration of the PET-CT to the pCT are summarised in 
table 1. DIR was significantly superior to rigid registration for multiple metrics, as shown. A 
non-significant trend towards superiority of DIR was observed across all metrics for all 
structures. 
 
For all patients, a volumetric comparison of the metabolically active tumour volumes, 
before and after DIR, was used to examine the local deformation and ensure that the 
deformation algorithm conserved volume in these regions. An average absolute difference 
in volume of 1.3cm3 (range -5 to 6.7cm3) was observed, with a maximum increase in volume 
of 6.7cm3 for one patient (48.9cm3 on PET-CT to 55.6cm3 on planning CT). 
 
Quantitative analysis of co-registration of relapse CT to pCT was performed for the five 
patients for whom co-registration had been deemed clinically acceptable. Table 2 
summarises these results, showing superiority of DIR for multiple metrics, with a trend 
towards DIR being superior to rigid registration for all positional metrics and all structures. 
 
Table 1  
Quantitative evaluation of DIR and rigid registration between PET-CT and pCT using 
positional metrics 
Structure Registration 
PET CT to Planning CT (n=10) 
CI DSC IncI SI 
Oesophagus 
DIR 0.61 0.77 0.84 0.72 
Rigid 0.53 0.70 0.73 0.68 
p-value 0.17 0.16 0.04 0.60 
Trachea 
DIR 0.79 0.88 0.94 0.84 
Rigid 0.57 0.70 0.70 0.70 
p-value 0.002 0.01 0.002 0.08 
Descending Aorta 
DIR 0.86 0.93 0.92 0.95 
Rigid 0.78 0.88 0.88 0.88 
 
p-value 0.04 0.03 0.15 0.01 
 
Table 2  
Quantitative evaluation of DIR and rigid registration between relapse CT and pCT using 
positional metrics 
Structure Registration 
Relapse CT to Planning CT (n=6) 
CI DSC IncI SI 
Oesophagus 
DIR 0.61 0.74 0.87 0.65 
Rigid 0.37 0.51 0.59 0.45 
p-value 0.06 0.08 0.03 0.10 
Trachea 
DIR 0.83 0.91 0.93 0.90 
Rigid 0.51 0.66 0.63 0.70 
p-value 0.00 0.01 0.00 0.05 
Descending Aorta DIR 0.83 0.91 0.9 0.93 
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Rigid 0.63 0.75 0.76 0.73 
 
p-value 0.06 0.06 0.10 0.04 
 
PET-based GTV and PTV delineation 
 
Table 3 shows the length and volume of GTV and PTVs.  Median GTVPET-CT and GTVTP lengths 
were 4cm (range 0.5-7cm) and 7cm (range 3.5-10.5cm) (p<0.003) respectively. Median 
PTVPET-CT and PTVTP lengths were 10cm (range 6-13cm) and 13.5cm (range 9.5-16cm) 
(p<0.003). A mean reduction of 1.7cm (0.5 to -4cm) was observed in the superior direction 
while the inferior extension had a mean reduction of 1.4cm (3 to -4cm).  
 
Table 3 
A comparison of PTV length and PTV volume for PET-CT derived and treatment planning CT 
derived structures.  
Patient  
Length (cm) Volume (cm3) 
GTVPET-CT PTVPET-CT GTVTP PTVTP GTVPET-CT PTVPET-CT GTVTP PTVTP 
1 6.5 12.5 6.5 14 39.4 318.8 51.5 371.5 
2 0.5 6.5 3.5 9.5 2.6 129.5 9.4 310.6 
3 5 11 8 14 33.5 305.7 45.3 295.9 
4 4 10 6.5 16 18.3 246.1 20.6 415 
5 3 9 9 15 13.1 204.8 31.3 388.1 
6 7 13 9 15 36.8 361.6 48.4 454.9 
7 4 10 7 13.5 20.3 241.5 34.7 247.7 
8 2 8 7 12 10.5 220.5 33.7 251.3 
9 5 11 5 11 96.4 493.6 42 457.4 
10 2 8 3.5 9.5 5 149.5 6.7 140.6 
Note: Patients 1-6 represent the relapse patients. 
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Figure 2: Examples of the location of GTVTP, PTVTP, GTVPET-CT and PTVPET-CT relative to the high 
dose region; (a) For patient 3, the PTVPET-CT extends posteriorly compared to PTVTP but is still 
contained within the high dose region (b) For patient 5, both the GTVPET-CT and PTVPET-CT are 
contained within the high dose region. 
 
A comparison of the positions of GTVs and PTVs, relative to the high dose region (i.e. the 
volume covered by 95% of the prescribed treatment dose) can be observed for two patients 
in figure 2.  
 
Relapse Patients 
 
Dosimetric analysis was also performed to assess the coverage of GTVrelapse structures, 
relative to the PTVPET-CT and PTVTP structures. Patient 2 was omitted due to a stent inserted 
in the oesophagus prior to the relapse CT, which meant image co-registration was not 
possible. Dosimetric analysis showed that, with the exception of patient 2, 100% of the 
relapse volumes were contained within the V95%. The IncI was used to examine whether 
any correlation exists between the location of the relapse volume and the GTVPET-CT and 
PTVPET-CT. Results are summarised in table 4. 
 
Table 4 
The IncI looks at the probability that a voxel of GTVrelapse is contained within GTVPET-CT and 
PTVPET-CT 
Patient 
 Inclusiveness Index 
GTVrelapse to GTVPET-CT GTVrelapse to CTVPET-CT GTVrelapse to PTVPET-CT 
1 0.69 0.99 1 
2 * * * 
3 0.84 1 1 
4 0.6 0.85 0.94 
5 0.45 0.88 1 
6 0.7 0.93 1 
*Omitted due to oesophageal stent insertion. 
 
DISCUSSION 
 
The benefits of the integration of PET-CT into the planning process have been widely 
discussed [27-30].  However, this process is challenging, mainly due to the variations in 
patient setup between diagnostic and planning scans. The availability of a dedicated 
planning PET-CT for oesophageal carcinoma is not widely accessible. Therefore, the use of 
image co-registration to facilitate this integration is highly relevant. This is in view of the 
importance of improving the quality of GTV delineation in order to avoid a geographic miss. 
It can also assist in identifying a suitable target for future dose escalation studies. This study 
shows that image co-registration offers a suitable method of incorporating diagnostic PET-
CT imaging to the treatment planning process. 
 
There is no definitive method of validating the accuracy of a registration but fixed landmark 
placement and ROI-based comparisons have been used [31-32]. This study applied an ROI-
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based method of validation, choosing structures which were easy to identify and contour, 
and adjacent to the treatment field. Both qualitative and quantitative analysis showed that 
DIR was superior to rigid registration in accurately registering diagnostic PET-CT and relapse 
CT imaging to a pCT.  Co-registration using DIR was significantly superior by multiple 
positional metrics, with a non-significant trend to superiority in all comparisons.  
Importantly, blinded clinical qualitative assessment found that the co-registration of PET-CT 
to pCT was clinically acceptable for planning purposes and superior with DIR.  The difference 
between DIR and rigid registrations was more pronounced in the relapse CT to pCT 
registrations. This is perhaps unsurprising as a significant period of time has passed between 
scans; relapse CT scans were acquired an average of 11 months after the planning CT (range 
of  4-17 months) compared to PET-CT scans which were acquired an average of 1.5 months 
prior to treatment commencing (range of 0.1-4.5 months). Therefore large changes to 
external anatomy in this time-frame are expected. Despite this, visual assessment of the DIR 
by a clinical oncologist and physicist team found them to be clinically acceptable for all but 
one patient who had an oesophageal stent inserted.  
 
Results showed that using t PET-CT registered to pCT to derive a GTV will result in a shorter 
PTV length than contouring according to the current clinical protocol. Results also show a 
median reduction in superior PTV length of 1.7cm and a median reduction in the inferior 
PTV length of 1.4cm when using registered PET-CT in conjunction with the planning CT. This 
data is consistent with several previous studies which have shown that the addition of PET 
imaging leads to a reduction in PTV length [6, 9, 33] and volume [34].  
 
This study used DIR to analyse the pattern of recurrence for a group of patients, to 
determine whether any correlation exists between the site of these recurrences and the 
PTVPET-CT. This has previously been examined for head and neck patients [35]. Local 
recurrences were classified as ‘infield’, ‘marginal’ or ‘out-of-field’ if more than 95%, 20-94% 
and less than 20% of the recurrence volume was within the 95% isodose line [23]. 
Dosimetric analysis for the 5 relapse patients studied showed that all relapse volumes were 
in the high dose treatment field within both the PTVPET-CT and PTVTP. This is supported by 
previous work which examined the pattern of local recurrence and found that the majority 
of recurrences occurred within the treatment field [2]. The IncI was also used to determine 
whether this recurrence volume was contained within PTVPET-CT and PTVTP structures. An 
average IncI of 0.66 (range of 0.45-0.84) suggests some degree of correlation between the 
relapse volumes and the GTVPET-CT. A large correlation exists between the relapse volumes 
and CTVPET-CT with an average IncI of 0.93 (range of 0.85-1). This preliminary data suggests 
local recurrences are predominantly due to resistant disease rather than a geometric miss. 
Dose escalation using a synchronous boost may be necessary to reduce this likelihood of 
treatment failure. The suggested correlation between the relapse volumes and CTVPET-CT 
suggests that the metabolically active PET volume, plus a margin, could be used as a target 
in dose escalation studies. These findings support the planned UK SCOPE2 trial where dose 
escalation using a synchronous boost will be used, although the sample size is small. 
 
Limitations 
 
There are several limitations to this study. The patient sample is small and further 
investigation using a larger patient cohort is required to verify these results.  There is also a 
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lack of a validated method of GTV delineation using PET-CT, including the optimum SUV 
maximum threshold for delineating the metabolically active volume on the PET-CT [10-13]. 
A prior study focusing on cervical cancer showed that the minimum threshold representing 
tumour volume was 40% of maximum SUV with values less than this included additional 
background uptake [36]. An additional study reported that values of greater than 80% SUV 
max should be avoided as tumour volumes are small and the partial volume effect is 
pronounced [37]. Consequently, this study uses a pragmatically determined value of 50% of 
maximum SUV thresholding. This reflects a compromise between the two and the cut off 
used by diagnostic PET radiologists when reporting on the length of the tumour. Therefore 
50% of maximum SUV represented current clinical practice. 
 
This study has shown, through both quantitative and qualitative analysis, that DIR allows 
more accurate image co-registration than rigid registration for both PET-CT and relapse CT 
to pCT registration. However, the time interval between the pCT and PET-CT and, in 
particular, the relapse CT, means that significant changes to patient anatomy (e.g. weight 
loss) and tumour volume may have occurred. This can result in inaccuracies in the image co-
registration. This was observed for one patient where an oesophageal stent had been 
inserted prior to acquisition of the relapse CT. A detailed check of image registration should 
be carried out prior to the transfer of PET-CT and relapse volumes to the pCT.  This time 
interval is of critical importance in deciding whether it is appropriate to use a diagnostic 
PET-CT in the radiotherapy planning process; the potential for tumour progression in the 
intervening period needs to be considered.  
 
CONCLUSION 
 
DIR is superior to rigid registration and represents a feasible and practical approach for 
integrating PET-CT imaging to the treatment planning process for oesophageal radiotherapy.   
Using DIR to examine the pattern of relapse is a valuable tool in assessing the quality of 
radiotherapy treatment. It enables comparison of relapse CT data with pCT data to 
determine whether current target delineation is appropriate. Analysis of the pattern of local 
recurrence for five patients suggests geometric miss of the volume due to the initial 
treatment planning was unlikely, and treatment intensification using a synchronous boost 
could have clinical benefits; a metabolic, biological tumour volume derived from the PET-CT 
represents a potential target.  
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